UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30,~~March 31, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 0-21810

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)


Michigan		95-4318554
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
21680 Haggerty Road, Northville, MI		48167
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (248) 504-0500

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, no par value	THRM	Nasdaq

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At ~~July 28, 2022,~~April 21, 2023, there were ~~33,164,721~~33,127,634 issued and outstanding shares of Common Stock of the registrant.

GENTHERM INCORPORATED

TABLE OF CONTENTS





Part I. Financial Information			3
	Item 1.	Financial Statements (Unaudited)	3
		Consolidated Condensed Balance Sheets	3
		Consolidated Condensed Statements of Income	4
		Consolidated Condensed Statements of Comprehensive ~~(Loss)~~ Income	5
		Consolidated Condensed Statements of Cash Flows	6
		Consolidated Condensed Statements of Changes in Shareholders’ Equity	7
		Notes to Unaudited Consolidated Condensed Financial Statements	8
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3733
	Item 4.	Controls and Procedures	3935
Part II. Other Information			4036
	Item 1.	Legal Proceedings	4036
	Item 1A.	Risk Factors	4036
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4036
	Item 6.	Exhibits	4137
Signatures			4238

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)


	June 30, 2022			December 31, 2021			March 31, 2023			December 31, 2022
ASSETS
Current Assets:
Cash and cash equivalents	$	157,258		$	190,606		$	166,630		$	153,891
Accounts receivable, net		207,364			182,987			256,715			247,131
Inventory:
Raw materials		122,371			96,426			137,829			136,217
Work in process		8,989			9,495			17,091			17,695
Finished goods		56,424			53,556			63,543			64,336
Inventory, net		187,784			159,477			218,463			218,248
Other current assets		40,320			32,775			69,691			64,597
Total current assets		592,726			565,845			711,499			683,867
Property and equipment, net		149,907			155,270			242,143			244,480
Goodwill		62,935			66,033			120,955			119,774
Other intangible assets, net		31,968			37,554			72,051			73,933
Operating lease right-of-use assets		25,924			24,387			31,024			29,945
Deferred income tax assets		67,112			69,630			73,004			69,840
Other non-current assets		16,474			16,624			18,070			17,461
Total assets	$	947,046		$	935,343		$	1,268,746		$	1,239,300
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	147,136		$	122,727		$	207,887		$	182,225
Current lease liabilities		5,376			5,669			8,093			7,143
Current maturities of long-term debt		2,500			2,500			1,996			2,443
Other current liabilities		84,206			82,193			88,896			93,814
Total current liabilities		239,218			213,089			306,872			285,625
Long-term debt, less current maturities		35,000			36,250			232,558			232,653
Non-current lease liabilities		18,721			19,789			19,740			20,538
Pension benefit obligation		6,116			6,832			3,326			3,638
Other non-current liabilities		4,796			5,577			25,932			24,573
Total liabilities	$	303,851		$	281,537		$	588,428		$	567,027
Shareholders’ equity:
Common Stock:
No par value; 55,000,000 shares authorized 33,132,691 and 33,008,185 issued and outstanding at June 30, 2022 and December 31, 2021, respectively		121,088			118,646
No par value; 55,000,000 shares authorized 33,126,702 and 33,202,082 issued and outstanding at March 31, 2023 and December 31, 2022, respectively								112,420			122,658
Paid-in capital		5,720			5,866			5,379			5,447
Accumulated other comprehensive loss		(68,648	)		(36,922	)		(36,101	)		(46,489	)
Accumulated earnings		585,035			566,216			598,620			590,657
Total shareholders’ equity		643,195			653,806			680,318			672,273
Total liabilities and shareholders’ equity	$	947,046		$	935,343		$	1,268,746		$	1,239,300

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2022			2021			2023			2022
Product revenues	$	260,715		$	266,005		$	528,372		$	554,540		$	363,625		$	267,657
Cost of sales		201,338			186,792			404,882			387,658			282,495			203,544
Gross margin		59,377			79,213			123,490			166,882			81,130			64,113
Operating expenses:
Net research and development expenses		19,325			18,227			39,759			35,830			25,145			20,434
Selling, general and administrative expenses		31,943			27,223			61,251			55,749			37,042			29,308
Restructuring expenses		374			2,091			555			2,882			1,269			181
Total operating expenses		51,642			47,541			101,565			94,461			63,456			49,923
Operating income		7,735			31,672			21,925			72,421			17,674			14,190
Interest expense, net		(1,430	)		(630	)		(1,999	)		(1,669	)		(4,144	)		(569	)
Foreign currency gain (loss)		4,552			(515	)		6,769			258
Foreign currency (loss) gain														(2,069	)		2,217
Other income		134			12			338			3			230			204
Earnings before income tax		10,991			30,539			27,033			71,013			11,691			16,042
Income tax expense		3,919			5,748			8,214			13,313			3,728			4,295
Net income	$	7,072		$	24,791		$	18,819		$	57,700		$	7,963		$	11,747
Basic earnings per share	$	0.21		$	0.75		$	0.57		$	1.75		$	0.24		$	0.36
Diluted earnings per share	$	0.21		$	0.74		$	0.56		$	1.72		$	0.24		$	0.35
Weighted average number of shares – basic		33,119			33,100			33,077			33,025			33,182			33,035
Weighted average number of shares – diluted		33,426			33,544			33,422			33,469			33,386			33,377

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE ~~(LOSS)~~ INCOME

(In thousands)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2022			2021			2023		2022
Net income	$	7,072		$	24,791		$	18,819		$	57,700		$	7,963	$	11,747
Other comprehensive (loss) income:
Other comprehensive income:
Pension benefit obligations		27			—			56			—			4		29
Foreign currency translation adjustments		(22,700	)		4,528			(31,994	)		(8,624	)		8,255		(9,294	)
Unrealized (loss) gain on foreign currency derivative securities, net of tax		(247	)		(48	)		217			(570	)
Unrealized gain on foreign currency derivative securities, net of tax														2,129		464
Unrealized loss on commodity derivative securities, net of tax		—			—			(5	)		—			—		(5	)
Other comprehensive (loss) income, net of tax		(22,920	)		4,480			(31,726	)		(9,194	)
Comprehensive (loss) income	$	(15,848	)	$	29,271		$	(12,907	)	$	48,506
Other comprehensive income (loss), net of tax														10,388		(8,806	)
Comprehensive income													$	18,351	$	2,941

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2023			2022
Operating Activities:
Net income	$	18,819		$	57,700		$	7,963		$	11,747
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		18,635			19,571			13,583			9,577
Deferred income taxes		(997	)		(225	)		(1,786	)		(778	)
Non-cash stock based compensation		5,263			7,663
Stock based compensation								2,023			2,279
Loss on disposition of property and equipment		518			496			16			107
Provisions for inventory								1,704			747
Other		708			(262	)		(44	)		256
Changes in assets and liabilities:
Accounts receivable, net		(31,762	)		11,647			(8,237	)		(25,788	)
Inventory		(33,637	)		(17,211	)		(1,137	)		(18,863	)
Other assets		(10,443	)		8,408			(6,417	)		(10,716	)
Accounts payable		27,768			(289	)		24,289			34,097
Other liabilities		1,442			(3,136	)		(6,848	)		(3,349	)
Net cash (used in) provided by operating activities		(3,686	)		84,362
Net cash provided by (used in) operating activities								25,109			(684	)
Investing Activities:
Purchases of property and equipment		(15,448	)		(20,669	)		(6,294	)		(5,659	)
Proceeds from the sale of property and equipment		81			10			17			52
Proceeds from deferred purchase price of factored receivables								3,728			—
Cost of technology investments		(350	)		(5,200	)		—			(350	)
Net cash used in investing activities		(15,717	)		(25,859	)		(2,549	)		(5,957	)
Financing Activities:
Repayments of debt		(1,250	)		(143,731	)		(564	)		—
Proceeds from the exercise of Common Stock options		569			6,292			263			569
Taxes withheld and paid on employees' share-based payment awards		(4,464	)		(2,117	)		(2,667	)		(4,319	)
Acquisition contingent consideration payment		—			(69	)
Cash paid for the repurchase of Common Stock								(9,997	)		—
Net cash used in financing activities		(5,145	)		(139,625	)		(12,965	)		(3,750	)
Foreign currency effect		(8,800	)		(360	)		3,144			(2,298	)
Net decrease in cash and cash equivalents		(33,348	)		(81,482	)
Net increase (decrease) in cash and cash equivalents								12,739			(12,689	)
Cash and cash equivalents at beginning of period		190,606			268,345			153,891			190,606
Cash and cash equivalents at end of period	$	157,258		$	186,863		$	166,630		$	177,917
Supplemental disclosure of cash flow information:
Cash paid for taxes	$	8,642		$	8,563		$	5,536		$	3,267
Cash paid for interest	$	909		$	1,455			3,235			421
Non-Cash Investing Activities:
Period-end balance of accounts payable for property and equipment							$	2,370		$	2,437
Deferred purchase price of receivables factored in the period								4,739			—

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands)

(Unaudited)


																										Accumulated
																										Other
																	Common Stock						Paid-in			Comprehensive			Accumulated
																	Shares			Amount			Capital			Loss			Earnings		Total
Balance at December 31, 2022																		33,202		$	122,658		$	5,447		$	(46,489	)	$	590,657	$	672,273
Net income																		—			—			—			—			7,963		7,963
Other comprehensive income																		—			—			—			10,388			—		10,388
Stock compensation, net																		94			(241	)		(68	)		—			—		(309	)
Stock repurchase																		(169	)		(9,997	)		—			—			—		(9,997	)
Balance at March 31, 2023																		33,127		$	112,420		$	5,379		$	(36,101	)	$	598,620	$	680,318

									Accumulated																	Accumulated
									Other																	Other
	Common Stock					Paid-in			Comprehensive			Accumulated					Common Stock						Paid-in			Comprehensive			Accumulated
	Shares		Amount			Capital			Loss			Earnings		Total			Shares			Amount			Capital			Loss			Earnings		Total
Balance at December 31, 2021		33,008	$	118,646		$	5,866		$	(36,922	)	$	566,216	$	653,806			33,008		$	118,646		$	5,866		$	(36,922	)	$	566,216	$	653,806
Net income		—		—			—			—			11,747		11,747			—			—			—			—			11,747		11,747
Other comprehensive loss		—		—			—			(8,806	)		—		(8,806	)		—			—			—			(8,806	)		—		(8,806	)
Stock compensation, net		119		(814	)		(146	)		—			—		(960	)		119			(814	)		(146	)		—			—		(960	)
Balance at March 31, 2022		33,127		117,832			5,720			(45,728	)		577,963		655,787			33,127		$	117,832		$	5,720		$	(45,728	)	$	577,963	$	655,787
Net income		—		—			—			—			7,072		7,072
Other comprehensive loss		—		—			—			(22,920	)		—		(22,920	)
Stock compensation, net		6		3,256			—			—			—		3,256
Balance at June 30, 2022		33,133	$	121,088		$	5,720		$	(68,648	)	$	585,035	$	643,195


									Accumulated
									Other
	Common Stock					Paid-in			Comprehensive			Accumulated
	Shares		Amount			Capital			Loss			Earnings		Total
Balance at December 31, 2020		32,921	$	121,073		$	7,458		$	(14,982	)	$	472,782	$	586,331
Net income		—		—			—			—			32,909		32,909
Other comprehensive loss		—		—			—			(13,674	)		—		(13,674	)
Stock compensation, net		190		8,527			(1,335	)		—			—		7,192
Balance at March 31, 2021		33,111		129,600			6,123			(28,656	)		505,691		612,758
Net income		—		—			—			—			24,791		24,791
Other comprehensive income		—		—			—			4,480			—		4,480
Stock compensation, net		34		3,142			39			—			—		3,181
Balance at June 30, 2021		33,145	$	132,742		$	6,162		$	(24,176	)	$	530,482	$	645,210

See accompanying notes to the consolidated condensed financial statements.

Note 1 – Overview

Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is athe global ~~developer, manufacturer and marketer~~market leader of innovative thermal management ~~technologies for a broad range of heating, cooling and temperature control applications, primarily for the automotive and medical industries~~ and pneumatic comfort technologies for the automotive ~~industry. Within the~~and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive ~~industry, our products provide~~interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, ~~for passenger climate comfort and convenience,~~cable systems, lumbar and massage comfort solutions, valve ~~system technologies, battery thermal management~~systems, and ~~cell connecting systems. Within the medical industry our products provide patient temperature management solutions.~~other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major ~~automotive~~ original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the US, China, Germany and Brazil. The Company is also developing a number of new technologies and products that ~~are expected to~~will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to ~~create~~ new product applications for existing and new and adjacent markets.

Basis of Presentation and Significant Accounting Policies

The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments), considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Principles of Consolidation

The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in ~~affiliates~~entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in ~~affiliates~~entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

Variable Interest Entities

The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $5,200 as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, and is recorded in Other non-current assets in the consolidated condensed balance sheets.

Revenue Recognition

The Company has no material contract assets or contract liabilities as of ~~June 30, 2022.~~March 31, 2023.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $~~1,772~~3,029 and $~~1,946~~2,239 as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program.

Note 2 – ~~New Accounting Pronouncements~~Acquisitions

Alfmeier Präzision SE

On August 1, 2022, the Company acquired 100% of the equity interests of Alfmeier, a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort.

The total consideration transferred was $170,700. The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date.

The acquisition was accounted for as a business combination. The following table summarizes the purchase consideration and preliminary estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments:


	Initial Allocation as of August 1, 2022			Measurement Period Adjustments			Revised Allocation as of March 31, 2023
Purchase price, cash consideration, net of cash acquired	$	164,887		$	5,813		$	170,700
								—
Accounts receivable		24,988			(121	)		24,867
Inventory		36,026			(106	)		35,920
Prepaid expenses and other assets		20,920			(74	)		20,846
Operating lease right-of-use assets		4,608			—			4,608
Property and equipment		89,942			1,242			91,184
Other intangible assets		22,668			8,791			31,459
Goodwill		43,678			(9,184	)		34,494
Assumed liabilities		(55,994	)		975			(55,019	)
Deferred tax liabilities		(21,949	)		4,290			(17,659	)
Net assets acquired	$	164,887		$	5,813		$	170,700

During the three months ended March 31, 2023, the Company did not record any measurement period adjustments. The preliminary fair values of assets acquired and liabilities assumed are subject to change as the Company completes its analysis of the fair values as of the date of acquisition.

~~Reference Rate Reform~~The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired:


	Preliminary Fair Value		Weighted Average Life (in years)
Definite-lived:
Customer related	$	19,812		14
Technology		11,647		9
Total	$	31,459

~~In March 2020,~~9

The fair value of the ~~FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform~~intangible assets was based on ~~Financial Reporting”. ASU 2020-04 provides practical expedients~~third-party valuations and ~~exceptions for applying GAAP to contracts, hedging relationships,~~management’s estimates, generally utilizing income and ~~other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments~~market approaches. Goodwill recognized in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes ortransaction is ~~subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent~~primarily attributable to the ~~date of the issuance of a final update, up~~Company’s expected future economic benefits from combining operations to ~~the date that financial statements are available to be issued.~~offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The ~~adoption of this standard~~goodwill is not expected to ~~have~~be deductible for tax purposes.

The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022:


	Three Months Ended March 31, 2022
Product revenues	$	333,756
Net income		8,567

Jiangmen Dacheng Medical Equipment Co. Ltd

On July 13, 2022, the Company acquired 100% of the equity interests of Dacheng and its wholly owned subsidiary, IOB Medical, Inc. Dacheng, a ~~material impact~~privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site.

The total consideration transferred was $35,048. The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $500. These cash payments were accounted for as compensation expense and recorded as a component of selling, general and administrative expense ratably over the service period.


	Initial Allocation as of July 13, 2022			Measurement Period Adjustments			Revised Allocation as of March 31, 2023
Purchase price, cash consideration, net of cash acquired	$	35,048		$	—		$	35,048
								—
Accounts receivable		746			(84	)		662
Inventory		1,942			(177	)		1,765
Prepaid expenses and other assets		152			22			174
Operating lease right-of-use assets		841			—			841
Property and equipment		684			—			684
Other intangible assets		19,094			965			20,059
Goodwill		22,995			(3,979	)		19,016
Assumed liabilities		(2,799	)		(40	)		(2,839	)
Deferred tax liabilities		(8,607	)		3,293			(5,314	)
Net assets acquired	$	35,048		$	—		$	35,048

The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired:


	Preliminary Fair Value		Weighted Average Life (in years)
Definite-lived:
Customer related	$	12,837		12
Technology		4,749		12
Indefinite-lived:
Tradenames		2,473		—
Total	$	20,059

Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes.

The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial ~~statements.~~statements are presented.

Note 3 – Restructuring and Impairments

The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs.

These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination.

Manufacturing Footprint Rationalization

~~In September~~During 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company ~~is relocating~~relocated and ~~consolidating~~consolidated certain automotive electronics manufacturing plants in North America and China. During 2021, the Company completed the closures and relocation of its automotive electronics manufacturing operations from Burlington, Canada to Celaya, Mexico and from Longgang, Shenzhen, China to Bantian, Shenzhen, China. As of June 30, 2022, the electronics manufacturing in Acuña, Mexico continues to transition to Celaya, Mexico.

During the three ~~and six~~ months ended ~~June 30,~~March 31, 2023, the Company did not recognize any restructuring expense. During the three months ended March 31, 2022, the Company recognized restructuring expense of $0 ~~and $~~50~~, respectively,~~ for employee separation costs and $97 ~~and $198, respectively, for other costs. During the three and six months ended June 30, 2021, the Company recognized restructuring expense of $759~~ ~~and $965~~ ~~for employee separation costs, respectively, $~~97 ~~and $192~~ ~~for accelerated depreciation, respectively, and $488~~ ~~and $652~~101 for other ~~costs, respectively.~~costs.

The Company has recorded approximately $~~10,353~~10,359 of restructuring expenses since the inception of this program and as of ~~June 30, 2022,~~March 31, 2023, $~~538~~588 remains accrued.~~Actions under the Plan are expected to be substantially completed by the end of 2022~~ ~~and future expenses are expected to be less than $1,000~~.

Other Restructuring Activities

~~As part of the Company’s continued efforts to optimize its cost structure, the~~The Company has undertaken several discrete restructuring actions. During the three ~~and six~~ months ended ~~June 30,~~March 31, 2023, the Company recognized $1,206 for employee separation costs and $63 of other costs. During the three months ended March 31, 2022, the Company recognized $~~277~~30 ~~and $307, respectively,~~ for other ~~costs. During the three and six months ended June 30, 2021, the Company recognized $747~~ ~~and $1,073, respectively, of employee separation~~ costs. These restructuring expenses were primarily associated with restructuring actions focused on the ~~rotation of our manufacturing footprint to best cost locations and the~~ reduction of global overhead costs.

911

Restructuring Expenses By Reporting Segment

The following table summarizes restructuring expense for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ by reporting segment:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2022		2021		2022		2021		2023		2022
Automotive	$	374	$	1,075	$	555	$	1,866	$	1,074	$	181
Medical		—		—		—		—		—		—
Corporate		—		1,016		—		1,016		195		—
Total	$	374	$	2,091	$	555	$	2,882	$	1,269	$	181

Restructuring Liability

Restructuring liabilities are classified as ~~Other~~other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the ~~six~~three months ended ~~June 30, 2022:~~March 31, 2023:


	Employee Separation Costs		Other Related Costs			Total
Balance at December 31, 2022	$	588	$	—		$	588
Additions, charged to restructuring expenses		1,206		63			1,269
Cash payments		—		(63	)		(63	)
Currency translation		16		—			16
Balance at March 31, 2023	$	1,810	$	—		$	1,810

Impairments – Non-Automotive Electronics Business

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $9,378, $5,601 and $690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.

Employee Separation Costs

Other Related Costs

Total

Balance at December 31, 2021

$
1,494

$
—

$
1,494

Additions, charged to restructuring expenses

—

131

131

Cash payments

(544
)

(131
)

(675
)
Non-cash utilization

—

—

—

Change in estimate

50

—

50

Currency translation

(18
)

—

(18
)
Balance at March 31, 2022

$
982

$
—

$
982

Additions, charged to restructuring expenses

—

374

374

Cash payments

(83
)

(97
)

(180
)
Non-cash utilization

—

—

—

Change in estimate

—

—

—

Currency translation

(32
)

—

(32
)
Balance at June 30, 2022

$
867

$
277

$
1,144

During the three months ended March 31, 2023, the Company recorded non-cash impairment charges of $1,419 for the write down of inventory within the Automotive segment. This charge is recorded in Cost of sales.

The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.

Note 4 – Details of Certain Balance Sheet Components


	June 30, 2022		December 31, 2021		March 31, 2023		December 31, 2022
Other current assets:
Billable tooling					$	16,296	$	15,267
Income tax and other tax receivable						14,048		15,041
Notes receivable	$	12,598	$	13,033		13,075		12,127
Income tax and other tax receivable		12,583		10,681
Prepaid expenses		6,409		3,407		8,800		6,239
Billable tooling		4,996		3,778
Short-term derivative financial instruments						8,548		6,564
Receivables due from factor						5,987		5,490
Other		3,734		1,876		2,937		3,869
Total other current assets	$	40,320	$	32,775	$	69,691	$	64,597
Other current liabilities:
Accrued employee liabilities	$	26,588	$	28,818	$	29,119	$	32,031
Liabilities from discounts and rebates		24,317		27,343		26,148		26,640
Income tax and other taxes payable		14,838		17,068		16,413		14,459
Accrued warranty		1,899		1,916		2,821		2,380
Derivative financial instruments		1,614		—
Restructuring		1,144		1,494		1,810		588
Other		13,806		5,554		12,585		17,716
Total other current liabilities	$	84,206	$	82,193	$	88,896	$	93,814

1012

Note 5 – Goodwill and Other Intangibles

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, for the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 was as follows:

Automotive

Medical

Total

Balance as of December 31, 2021

$
37,329

$
28,704

$
66,033

Exchange rate impact

(2,240
)

(858
)

(3,098
)
Balance as of June 30, 2022

$
35,089

$
27,846

$
62,935


	Automotive		Medical		Total
Balance as of December 31, 2022	$	73,069	$	46,705	$	119,774
Currency translation		949		232		1,181
Balance as of March 31, 2023	$	74,018	$	46,937	$	120,955

Other Intangible Assets

Other intangible assets and accumulated amortization balances as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 were as follows:


	June 30, 2022							December 31, 2021							March 31, 2023							December 31, 2022
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value
Definite-lived:
Customer relationships	$	82,828	$	(60,761	)	$	22,067	$	90,448	$	(64,105	)	$	26,343	$	113,909	$	(68,795	)	$	45,114	$	112,286	$	(65,748	)	$	46,538
Technology		27,236		(23,411	)		3,825		29,464		(24,487	)		4,977		45,340		(26,696	)		18,644		44,745		(25,709	)		19,036
Product development costs		18,243		(17,844	)		399		20,329		(19,772	)		557		19,051		(18,884	)		167		18,774		(18,456	)		318
Software development		1,007		—			1,007		1,007		—			1,007		1,007		—			1,007		1,007		—			1,007
Indefinite-lived:
Tradenames		4,670		—			4,670		4,670		—			4,670		7,119		—			7,119		7,034		—			7,034
Total	$	133,984	$	(102,016	)	$	31,968	$	145,918	$	(108,364	)	$	37,554	$	186,426	$	(114,375	)	$	72,051	$	183,846	$	(109,913	)	$	73,933

In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. We are not presently aware of any events or circumstances that would require us to revise the carrying value of our assets or liabilities as of ~~June 30, 2022.~~March 31, 2023.

Note 6 – Debt

The following table summarizes the Company’s debt as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021:~~2022:


	June 30, 2022						December 31, 2021						March 31, 2023						December 31, 2022
	Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
U.S. Revolving Note (U.S. Dollar denominations)		2.42	%	$	35,000			1.35	%	$	35,000
U.S. Revolving Note (Euro denominations)		—			—			—			—
DEG Vietnam Loan		5.21	%		2,500			5.21	%		3,750
Revolving Credit Facility (U.S. Dollar denominations)														6.28	%	$	232,000			5.80	%	$	232,000
Other loans													3.90% - 5.21%				1,555		3.89% - 5.21%				2,011
Finance leases													N/A				999		N/A				1,085
Total debt					37,500						38,750						234,554						235,096
Current maturities					(2,500	)					(2,500	)					(1,996	)					(2,443	)
Long-term debt, less current maturities				$	35,000					$	36,250					$	232,558					$	232,653

Credit Agreement

On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement amends and restates in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent.

1113

The Second Amended and Restated Credit Agreement provides for a $500,000 secured revolving credit facility (the “Revolving Credit Facility”) ~~(a $25,000~~ ~~increase from the revolving credit facility under the Amended and Restated Credit Agreement)~~, with a $50,000 sublimit for swing line loans and a $15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company had 0no outstanding letters of credit issued as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021.~~2022.

Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $200,000. The Second Amended and Restated Credit Agreement ~~extends the maturity of the Revolving Credit Facility from~~ ~~June 27, 2024~~ tomatures on June 10, 2027. ~~The outstanding principal and interest (of approximately $35,000~~ ~~as of June 10, 2022) under the Amended and Restated Credit Agreement continued and remained obligations under the Second Amended and Restated Credit Agreement.~~

The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders.

The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of ~~June 30, 2022,~~March 31, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable.

Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50%, Bank of America’s prime rate, or the Term SOFR rate plus 1.00%. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175% to 0.300%, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility.

The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125% and 2.125%, respectively, for Term SOFR Rate Loans and 0.125% and 1.125%, respectively, for Base Rate Loans.

Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverage Ratio, ~~$357,017~~$266,444 remained available as of ~~June 30, 2022~~March 31, 2023 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies.

In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $1,417, which have been capitalized and will be amortized into interest expense over the term of the credit facility. ~~In addition, unamortized deferred debt issuance costs of $144~~ ~~were written-off and recognized in Interest expense, net during three months ended June 30, 2022.~~

~~DEG Vietnam Loan~~14

The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began ~~November 2017~~ ~~and will end~~ ~~May 2023~~. Under the terms of the DEG Vietnam Loan, the Company must maintain a minimum Enhanced Equity Ratio, as defined by the DEG Vietnam Loan agreement, based on the financial statements of Gentherm’s wholly owned subsidiary, Gentherm Vietnam Co. Ltd. As of June 30, 2022, the Company was in compliance with the terms of the DEG Vietnam Loan.

The scheduled principal maturities of our debt as of ~~June 30, 2022~~March 31, 2023 were as follows:


	DEG Vietnam Note		U.S. Revolving Note		Total		U.S. Revolving Note		Other Debt		Total
2022	$	1,250	$	—	$	1,250
2023		1,250		—		1,250	$	—	$	1,892	$	1,892
2024		—		—		—		—		440		440
2025		—		—		—		—		152		152
2026		—		—		—		—		70		70
2027		—		35,000		35,000		232,000		—		232,000
2028								—		—		—
Total	$	2,500	$	35,000	$	37,500	$	232,000	$	2,554	$	234,554

Note 7 – Commitments and Contingencies

Legal and other contingencies

The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters ~~that~~which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated condensed results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves.

Product Liability and Warranty Matters

In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims or liabilities in the future or that it will not incur significant costs to defend such claims.

The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims ~~already~~ filed by customers, the warranty accrual is adjusted quarterly to reflect management’s ~~best~~ estimate of future claims.

The following is a reconciliation of the changes in accrued warranty costs:


	Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2023			2022
Balance at the beginning of the period	$	1,916		$	2,391		$	2,380		$	1,916
Warranty claims paid		(623	)		(599	)		(559	)		(334	)
Warranty expense for products shipped during the current period		818			1,043			988			354
Adjustments to warranty estimates from prior periods		(171	)		(314	)		(6	)		(152	)
Adjustments due to currency translation		(41	)		(26	)		18			(12	)
Balance at the end of the period	$	1,899		$	2,495		$	2,821		$	1,772

Other matters

Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. In addition, due to supply shortages of semiconductors, the Company has entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over rolling periods of 12-24 months, with volume commitments determined based on our anticipated production requirements. As of ~~June 30, 2022,~~March 31, 2023, the Company’s total commitments for these semiconductor chip agreements was $~~40,378~~40,593. Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of ~~June 30, 2022~~March 31, 2023 were immaterial.

Note 8 –Earnings Per Share

Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents.

The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2022		2021		2022		2021		2023		2022
Net income	$	7,072	$	24,791	$	18,819	$	57,700	$	7,963	$	11,747

Basic weighted average shares of Common Stock outstanding		33,119,085		33,100,230		33,077,029		33,025,432		33,181,828		33,034,872
Dilutive effect of stock options, restricted stock awards and restricted stock units		307,038		443,978		344,958		443,417		204,306		341,892
Diluted weighted average shares of Common Stock outstanding		33,426,123		33,544,208		33,421,987		33,468,849		33,386,134		33,376,764

Basic earnings per share	$	0.21	$	0.75	$	0.57	$	1.75	$	0.24	$	0.36
Diluted earnings per share	$	0.21	$	0.74	$	0.56	$	1.72	$	0.24	$	0.35

There were 0no shares excluded from the Company’s diluted earnings per share for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ on the basis that their inclusion would have an anti-dilutive impact on the calculation.

Note 9 – Financial Instruments

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, ~~acquisitions denominated in foreign currencies,~~ intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency and copper commodity hedging instruments, if any, to cost of sales in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in net cash provided by (used in) ~~provided by~~ operating activities in the Company’s consolidated condensed statements of cash flows.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

~~During the three months ended June 30, 2022, the~~The Company ~~entered into~~is party to a floating-to-fixed interest rate swap agreement with a notional amount of $100,000 and a maturity date of July 2025. This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the ~~expected~~Revolving Credit Facility borrowings ~~to be~~that were drawn for the acquisitions of Alfmeier and Dacheng. ~~See Note 15, “Subsequent Events,” for information about the Company’s acquisition activities.~~ The periodic changes in fair value is recognized in Interest expense, net.

~~During the three months ended June 30, 2022, the Company entered into forward contracts with a notional amount of $128,319~~ to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier. These forward contracts are not designated as hedging instruments. The periodic changes in fair value is recognized in Foreign currency gain (loss).

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of ~~June 30, 2022~~March 31, 2023 is as follows:

Asset Derivatives

Liability Derivatives

Fair Value
Hierarchy

Notional Amount

Balance Sheet
Location

Fair
Value

Balance Sheet
Location

Fair
Value

Net Asset/
(Liabilities)

Derivatives Designated as Cash Flow Hedges

Foreign currency derivatives

Level 2

$
14,075

Other current assets

$
588

Other current liabilities

$
—

$
588

Derivatives Not Designated as Hedging Instruments

Foreign currency derivatives

Level 2

$
128,319

Other current assets

$
1,403

Other current liabilities

$
921

$
482

Interest rate contracts

Level 2

$
100,000

Other current assets

$
—

Other current liabilities

$
693

$
693


				Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	69,108	Other current assets	$	6,474	Other current liabilities	$	—	$	6,474
Derivatives Not Designated as Hedging Instruments
Interest rate contracts	Level 2	$	100,000	Other current assets	$	2,073	Other current liabilities	$	—	$	2,073

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, ~~2021~~2022 is as follows:


				Asset Derivatives			Liability Derivatives								Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)		Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	13,974	Other current assets	$	294	Other current liabilities	$	—	$	294	Level 2	$	40,063	Other current assets	$	3,791	Other current liabilities	$	—	$	3,791
Commodity hedges	Level 2	$	309	Other current assets	$	6	Other current liabilities	$	—	$	6
Derivatives Not Designated as Hedging Instruments
Interest rate contracts												Level 2	$	100,000	Other current assets	$	2,772	Other current liabilities	$	—	$	2,772

Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows:


		Three Months Ended March 31,
	Location	2023			2022
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Cost of sales – income	$	1,059		$	153
	Other comprehensive income		2,683			610
Total foreign currency derivatives		$	3,742		$	763

Commodity derivatives	Cost of sales – income	$	—		$	19
	Other comprehensive loss		—			(6	)
Total commodity derivatives		$	—		$	13

Derivatives Not Designated as Hedging Instruments
Interest rate contracts	Interest income, net	$	(699	)	$	—
Total interest rate derivatives		$	(699	)	$	—

The Company did not incur any hedge ineffectiveness during the three months ended March 31, 2023 and 2022.

Three Months Ended June 30,

Six Months Ended June 30,

Location

2022

2021

2022

2021

Derivatives Designated as Cash Flow Hedges

Foreign currency derivatives

Cost of sales – income

$
333

$
529

$
486

$
1,007

Other comprehensive (loss) income

(316
)

(62
)

294

(729
)
Total foreign currency derivatives

$
17

$
467

$
780

$
278

Commodity derivatives

Cost of sales – income

$
—

$
—

$
19

$
—

Other comprehensive loss

—

—

(6
)

—

Total commodity derivatives

$
—

$
—

$
13

$
—

Derivatives Not Designated as Hedging Instruments

Foreign currency derivatives

Foreign currency gain (loss)

$
482

$
—

$
482

$
—

Total foreign currency derivatives

$
482

$
—

$
482

$
—

Interest rate contracts

Interest expense, net

$
(693
)

$
—

$
(693
)

$
—

Total interest rate derivatives

$
(693
)

$
—

$
(693
)

$
—

Accounts Receivable Factoring

The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is ~~party~~considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and excluded from accounts receivable in the consolidated condensed balance sheets. These factoring ~~agreement with HSBC Bank USA, National Association. Under~~arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated condensed balance sheets. Cash proceeds received upon the sale of the receivables are included in net cash provided by (used in) operating activities and the cash proceeds received on the deferred purchase price receivables are included in cash provided by investing activities. All factoring ~~agreement, we can sell receivables for certain~~arrangements incorporate customary representations, including representations as to validity of ~~our North America account debtors up to $~~amounts due, completeness of performance obligations and absence of commercial disputes.~~41,300~~

~~, on a revolving basis, subject to outstanding balances~~Receivables factored and ~~concentration limits. As of June 30, 2022, there were~~ 0 ~~outstanding receivables transferred under the receivable factoring agreement and our~~ availability under ~~the~~ receivables factoring ~~agreement was $~~agreements balances as of March 31, 2023 and December 31, 2022 were as follows:


	March 31, 2023		December 31, 2022
Receivables factored and outstanding	$	21,034	$	19,108
Amount available under the credit limit		3,321		5,034
Collective factoring limit	$	24,355	$	24,142

Trade receivables sold and factoring fees incurred during the three months ended March 31, 2023 and 2022 were as follows:~~32,431~~


	Three Months Ended March 31,
	2023		2022
Trade receivables sold	$	38,540	$	—
Factoring fees incurred		161		—

Note 10 – Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative instruments (see Note 9) and pension plan assets, the Company had 0no material financial assets and liabilities that were carried at fair value at ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021.~~2022. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for recent acquisitions (see Note 2). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of ~~June 30, 2022~~March 31, 2023, and December 31, ~~2021,~~2022, there were 0no other significant assets or liabilities measured at fair value on a non-recurring basis.

Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of ~~June 30, 2022,~~March 31, 2023, and December 31, ~~2021,~~2022, the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6). ~~Discount rates used to measure the fair value of Gentherm’s DEG Vietnam Loan are based on quoted swap rates. As of June 30, 2022, the carrying value of the DEG Vietnam Loan was $2,500~~ ~~as compared to an estimated fair value of $2,490. As of December 31, 2021, the carrying value of the DEG Vietnam Loan was $3,750~~ ~~as compared to an estimated fair value of $3,778~~.

Note 11 – Equity

In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) ~~to commence upon expiration of the prior stock repurchase program on December 15, 2020.~~. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023.

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. ~~The~~During the three months ended March 31, 2023, the Company ~~did~~ repurchased $09,997~~t make any repurchases~~ of shares under the 2020 Stock Repurchase Program ~~during the six months ended June 30, 2022, or June 30, 2021.~~with an average price paid per share of $59.27. The 2020 Stock Repurchase Program had $~~130,000~~120,003 of repurchase authorization remaining as of ~~June 30, 2022.~~March 31, 2023.

Note 12 – Reclassifications Out of Accumulated Other Comprehensive ~~Loss~~Income (Loss)

Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at March 31, 2022

$
(2,864
)

$
(43,482
)

$
618

$
—

$
(45,728
)
Other comprehensive (loss) income before reclassifications

—

(22,458
)

17

—

(22,441
)
Income tax effect of other comprehensive (loss) income before reclassifications

—

(242
)

(4
)

—

(246
)
Amounts reclassified from accumulated other comprehensive loss into net income

35

—

(333
)
a

—

a

(298
)
Income taxes reclassified into net income

(8
)

—

73

—

65

Net current period other comprehensive income (loss)

27

(22,700
)

(247
)

—

(22,920
)
Balance at June 30, 2022

$
(2,837
)

$
(66,182
)

$
371

$
—

$
(68,648
)

~~(a)~~

~~The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.~~

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at March 31, 2021

$
(3,451
)

$
(25,789
)

$
584

$
—

$
(28,656
)
Other comprehensive income before reclassifications

—

4,531

364

—

4,895

Income tax effect of other comprehensive income before reclassifications

—

(3
)

(79
)

—

(82
)
Amounts reclassified from accumulated other comprehensive loss into net income

—

—

(426
)
a

—

a

(426
)
Income taxes reclassified into net income

—

—

93

—

93

Net current period other comprehensive income (loss)

—

4,528

(48
)

—

4,480

Balance at June 30, 2021

$
(3,451
)

$
(21,261
)

$
536

$
—

$
(24,176
)

~~(a)~~

~~The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.~~

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at December 31, 2021

$
(2,893
)

$
(34,188
)

$
154

$
5

$
(36,922
)
Other comprehensive (loss) income before reclassifications

—

(31,612
)

780

13

(30,819
)
Income tax effect of other comprehensive loss before reclassifications

—

(382
)

(183
)

(3
)

(568
)
Amounts reclassified from accumulated other comprehensive loss into net income

70

—

(486
)
a

(19
)
a

(435
)
Income taxes reclassified into net income

(14
)

—

106

4

96

Net current period other comprehensive income (loss)

56

(31,994
)

217

(5
)

(31,726
)
Balance at June 30, 2022

$
(2,837
)

$
(66,182
)

$
371

$
—

$
(68,648
)


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives			Total
Balance at December 31, 2022	$	(1,067	)	$	(48,269	)	$	2,847			$	—		$	(46,489	)
Other comprehensive income before reclassifications		—			8,191			3,742				—			11,933
Income tax effect of other comprehensive income before reclassifications		—			64			(815	)			—			(751	)
Amounts reclassified from accumulated other comprehensive income into net income		6			—			(1,059	)	a		—	a		(1,053	)
Income taxes reclassified into net income		(2	)		—			261				—			259
Net current period other comprehensive income		4			8,255			2,129				—			10,388
Balance at March 31, 2023	$	(1,063	)	$	(40,014	)	$	4,976			$	—		$	(36,101	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

1819

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at December 31, 2020

$
(3,451
)

$
(12,637
)

$
1,106

$
—

$
(14,982
)
Other comprehensive (loss) income before reclassifications

—

(8,341
)

206

—

(8,135
)
Income tax effect of other comprehensive (loss) income before reclassifications

—

(283
)

(45
)

—

(328
)
Amounts reclassified from accumulated other comprehensive loss into net income

—

—

(935
)
a

—

a

(935
)
Income taxes reclassified into net income

—

—

204

—

204

Net current period other comprehensive loss

—

(8,624
)

(570
)

—

(9,194
)
Balance at June 30, 2021

$
(3,451
)

$
(21,261
)

$
536

$
—

$
(24,176
)


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives				Total
Balance at December 31, 2021	$	(2,893	)	$	(34,188	)	$	154			$	5			$	(36,922	)
Other comprehensive (loss) income before reclassifications		—			(9,154	)		763				13				(8,378	)
Income tax effect of other comprehensive loss before reclassifications		—			(140	)		(179	)			(3	)			(322	)
Amounts reclassified from accumulated other comprehensive loss into net income		35			—			(153	)	a		(19	)	a		(137	)
Income taxes reclassified into net income		(6	)		—			33				4				31
Net current period other comprehensive income (loss)		29			(9,294	)		464				(5	)			(8,806	)
Balance at March 31, 2022	$	(2,864	)	$	(43,482	)	$	618			$	—			$	(45,728	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of ~~June 30, 2022~~March 31, 2023 to be reclassified into earnings during the next twelve months. See Note 9 for additional information about derivative financial instruments and the effects from reclassification to net income.

Note 13 – Income Taxes

At the end of each interim period, the Company makes ~~its best~~an estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs.

The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs.

A summary of the provision for income taxes and the corresponding effective tax rate for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ is shown below:


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2022			2021			2023			2022
Income tax expense	$	3,919		$	5,748		$	8,214		$	13,313		$	3,728		$	4,295
Earnings before income tax	$	10,991		$	30,539		$	27,033		$	71,013		$	11,691		$	16,042
Effective tax rate		35.7	%		18.8	%		30.4	%		18.7	%		31.9	%		26.8	%

Income tax expense was $~~3,919~~3,728 for the three months ended ~~June 30, 2022~~March 31, 2023 on earnings before income tax of $~~10,991~~11,691, representing an effective tax rate of ~~35.7~~31.9 %. The tax amount included the effect of the settlement and closure of a multi-year state audit of $454. Adjusted for the audit impacts, the effective rate was 28.0%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”), and the quarterly accrual for uncertain tax positions, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects on ~~equity~~stock compensation vesting.

1920

Income tax expense was $~~5,748~~4,295 for the three months ended ~~June 30, 2021~~March 31, 2022 on earnings before income tax of $~~30,539~~16,042, representing an effective tax rate of ~~18.8~~26.8%. The effective tax rate differed from the U.S. Federal statutory rate of 21~~% primarily due to certain favorable tax effect on equity vesting and intercompany transactions in the second quarter of 2021, partially offset by unfavorable impact of GILTI.~~

~~Income tax expense was $8,214~~ ~~for the six months ended June 30, 2022 on earnings before income tax of $27,033, representing an effective tax rate of~~ ~~30.4%. The effective tax rate differed from the U.S. Federal statutory rate of~~ 2121.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects ~~of equity~~on stock compensation vesting.

~~Income tax expense was $13,313~~ ~~for the six months ended June 30, 2021 on earnings before income tax of $71,013, representing an effective tax rate of~~ ~~18.7%. The effective tax rate differed from the U.S. Federal statutory rate of~~ 21~~% primarily due to certain favorable tax effect on equity vesting and intercompany transactions in 2021, partially offset by the unfavorable impact of GILTI.~~

Note 14 – Segment Reporting

Segment information is used by management for making ~~strategic~~ operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

•

Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve systems, battery performance solutions, and automotive electronic and software systems.

•

Medical – this segment represents the results from our patient temperature management business within the medical industry.

The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment.

The tables below present segment information about the reported product revenues, depreciation and amortization and operating income (loss) of the Company for three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 and ~~2021.~~2022.

Three Months Ended June 30,

Automotive

Medical

Corporate

Total

2022

Product revenues

$
249,152

$
11,563

$
—

$
260,715

Depreciation and amortization

8,197

558

305

$
9,060

Operating income (loss)

24,026

(181
)

(16,110
)

$
7,735

2021

Product revenues

$
255,105

$
10,900

$
—

$
266,005

Depreciation and amortization

8,892

580

245

$
9,717

Operating income (loss)

43,544

113

(11,985
)

$
31,672


Six Months Ended June 30,	Automotive		Medical			Corporate			Total
Three Months Ended March 31,											Automotive		Medical			Corporate			Total
2023
Product revenues											$	352,692	$	10,933		$	—		$	363,625
Depreciation and amortization												12,290		978			265		$	13,583
Operating income (loss)												38,379		(493	)		(20,212	)	$	17,674
2022
Product revenues	$	507,016	$	21,356		$	—		$	528,372	$	257,864	$	9,793		$	—		$	267,657
Depreciation and amortization		16,863		1,162			610		$	18,635		8,667		604			306		$	9,577
Operating income (loss)		55,301		(1,032	)		(32,344	)	$	21,925		31,275		(851	)		(16,234	)	$	14,190
2021
Product revenues	$	534,475	$	20,065		$	—		$	554,540
Depreciation and amortization		17,945		1,164			462		$	19,571
Operating income (loss)		96,660		(418	)		(23,821	)	$	72,421

Automotive and Medical segment product revenues by product category for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2022		2021		2022		2021		2023		2022
Climate Control Seat	$	96,488	$	98,229	$	199,222	$	207,402	$	114,753	$	102,734
Seat Heaters		65,903		69,864		134,799		146,585		75,636		68,896
Lumbar and Massage Comfort Solutions (a)										38,738		—
Steering Wheel Heaters		28,951		26,697		57,687		55,561		36,347		28,736
Valve Systems (a)										26,994		—
Battery Performance Solutions										20,309		17,613
Automotive Cables		19,280		22,940		41,325		47,221		20,220		22,045
Battery Performance Solutions		17,451		17,577		35,064		35,337
Electronics		10,278		14,652		21,106		29,757		10,970		10,828
Other Automotive		10,801		5,146		17,813		12,612		8,725		7,012
Subtotal Automotive segment		249,152		255,105		507,016		534,475		352,692		257,864
Medical segment		11,563		10,900		21,356		20,065
Medical segment (b)										10,933		9,793
Total Company	$	260,715	$	266,005	$	528,372	$	554,540	$	363,625	$	267,657

(a)

Represents product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2)

(b)

Includes product revenues of $1,279 from Dacheng (acquired on July 13, 2022) - (see Note 2)

Total product revenues information by geographic area for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ is as follows (based on shipment destination):


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2022		2021		2022		2021		2023		2022
United States	$	102,617	$	102,174	$	206,738	$	217,461	$	141,452	$	104,122
China		31,391		33,857		69,744		67,372		46,654		38,353
South Korea		23,706		25,516		44,881		50,156		28,738		21,175
Germany		15,565		16,350		35,351		35,530		26,512		19,786
Czech Republic										17,650		10,808
Japan										15,222		11,816
Romania		11,519		14,866		24,273		29,951		12,533		12,755
Japan		12,886		17,633		24,702		35,553
Slovakia										11,596		8,536
Finland										10,133		7,893
Mexico										9,094		4,547
Other		63,032		55,609		122,682		118,517		44,041		27,866
Total Non-U.S.		158,098		163,831		321,634		337,079		222,173		163,535
Total Company	$	260,715	$	266,005	$	528,372	$	554,540	$	363,625	$	267,657

~~Note 15 – Subsequent Events~~

On May 4, 2022, the Company entered into a definitive purchase agreement to acquire the automotive business of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. Also on May 4, 2022, the Company entered into a put and call option agreement with one of the owners of Alfmeier for the real property in Germany on which Alfmeier’s headquarters is located. Pursuant to this agreement, the seller had a put to sell the headquarters to the Company and the Company had an option to purchase the headquarters post-closing of the acquisition of Alfmeier. Prior to the closing of the acquisition, Alfmeier and certain of its subsidiaries completed a series of carve-out transactions such that Alfmeier’s industrial and non-automotive business would not be acquired by the Company. On July 29, 2022, the Company completed the acquisition of Alfmeier through the acquisition of all shares in Alfmeier for a total purchase price of €~~181,500~~ ~~(approximately $184,871~~ at foreign exchange rates as of such date), net of cash and cash-like items and debt and debt-like items, and subject to customary adjustments related to Alfmeier’s net working capital as of the closing. The Alfmeier purchase price was increased by €~~4,000~~ ~~(approximately $4,074~~ at foreign exchange rates as of such date) at closing as a result of the resolution of certain Alfmeier tax matters prior to closing. Also, on July 29, 2022, the Company completed the acquisition of Alfmeier’s headquarters for a purchase price of €~~10,500~~ ~~(approximately $10,730~~ ~~at foreign exchange rates as of such date). The transactions were funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.~~

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. (“IOB”). Dacheng, a privately held company headquartered in Jiangmen, Guangdong Province, China, is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provides Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, while also expanding overall manufacturing capacity to include a low-cost manufacturing site. The Company acquired all shares in Dacheng for $~~34,300, net of cash and debt, and subject to customary adjustments related to Dacheng’s net working capital as of the closing. The purchase price may be increased by up to $3,000~~ ~~post-closing upon the achievement of certain milestones. Also, as part of the transaction but not the purchase price or net working capital, IOB retained the obligation to satisfy an existing $2,700~~ ~~consulting fee for work performed on IOB’s behalf. The transaction was funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.~~

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such asas: the expected light vehicle production in the Company’s key markets; the integration of recent acquisitions; the impact of macroeconomic and geopolitical conditions; the ~~COVID-19 pandemic on~~components of and our ~~financial statements, liquidity,~~ability to execute our updated strategic plan; long-term consumer and business as well as the global economy, global supply chain and automotive and medical industries, the impact of the conflict in Ukraine on our operations, the expected synergies and growth prospects following the closing of recent acquisitions, the significant supply disruptions and shiftstechnological trends in the ~~labor market currently faced by the automotive and medical industries, our ability~~Automotive industry and our ~~customers’ ability to maintain production levels,~~related market opportunity for our existing and new products and technologies; the ~~amount of borrowing availability under the Second Amended and Restated Credit Agreement and~~competitive landscape; the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource ~~needs~~needs; and our ability to finance sufficient working capital. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s ~~current~~reasonable expectations and beliefs. In making these statements we rely on assumptions and analysis based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we consider appropriate under the circumstances. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, ~~2021, as amended by Part II “Item 1A. Risk Factors” in our Current Report on Form 10-Q for the three months ended March 31,~~ 2022 and subsequent reports filed with or furnished to the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, ~~except for the recently consummated~~with reasonable frequency, we have entered into business combinations, acquisitions, ~~such~~divestitures, strategic investments and other significant transactions. Such forward-looking statements do not include the potential impact of any ~~other business combinations, acquisitions, divestitures, strategic investments and other significant~~such transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022.

Overview

Gentherm Incorporated is athe global ~~developer, manufacturer and marketer~~market leader of innovative thermal management ~~technologies for a broad range of heating, cooling and temperature control applications, primarily for the automotive and medical industries~~ and pneumatic comfort technologies for the automotive ~~industry. Within the~~and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive ~~industry, our products provide~~interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, ~~for passenger climate comfort and convenience,~~cable systems, lumbar and massage comfort solutions, valve ~~system technologies, battery thermal management~~systems, and ~~cell connecting systems. Within the medical industry our products provide patient temperature management solutions.~~other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major ~~OEMs~~original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the US, China, Germany and Brazil. The Company is also developing a number of new technologies and products that ~~are expected to~~will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to ~~create~~ new product applications for existing and new and adjacent markets.

Our sales are driven by the number of vehicles produced by the OEMs, which is ultimately dependent on consumer demand for automotive vehicles, our product content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. Historically, new vehicle demand and product content (i.e. vehicle features) have been driven by ~~macro-economic~~macroeconomic and other factors, such as interest rates, automotive manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Vehicle content has also been driven by trends in consumer preferences, such as preferences for smart devices and features, personalized user experience, and comfort, health and wellness. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, have had and could result in a significant reduction in automotive sales and production by our customers, which have had and would have an adverse effect on our business, results of operations and financial condition. InSince 2020, ~~and 2021, and continuing into 2022,~~ the automotive industry has experienced fluctuating demand and production disruptions related to supply chain challenges, facility closures, labor shortages, work stoppages and inflationary pressures, as ~~a result of the COVID-19 pandemic and associated macroeconomic conditions, as~~ described below. We believe our diversified OEM customer base and geographic revenue base, along with

our flexible cost structure, have well positioned us to withstand the impact of industry downturns ~~including the ongoing impact of the COVID-19 pandemic and associated economic conditions,~~ and benefit from industry upturns in the ordinary course. However, shifts in the mix of global automotive production to higher cost regions or to vehicles ~~with~~that contain less of our product content as well as continuing production challenges and inflationary pressures could adversely impact our profitability. In addition, we may be adversely impacted by volatility ~~weakness~~ or ~~accelerated growth~~weakness in markets for hybrid or electric vehicles specifically. We believe our products offer certain advantages for hybrid and electric vehicles, including improved energy efficiency, and position us well to withstand changes in the volume mix between vehicles driven by internal combustion engines and hybrid and other electric vehicles. We ~~also~~believe our industry is increasingly progressing towards a focus on human comfort and health, which is evidenced by increasing adoption rates for comfort products. We believe that products we are developing, such as ClimateSense®, and our acquisition of Alfmeier’s pneumatic comfort solutions, position us well to address trends in consumer preferences such as personalized user experience, comfort, health and wellness.

Recent Trends

General ~~Economic~~Macroeconomic and Geopolitical Conditions

~~The COVID-19 pandemic that began around December 2019 introduced significant volatility to~~Since 2020, the global economy has experienced significant volatility and disrupted supply chains, ~~and~~which has had a widespread adverse effect on the global automotive ~~industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021 and into 2022.~~

Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements. Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels.

~~The lingering impacts of COVID-19 throughout 2021 and into 2022~~industry. These macroeconomic conditions have ~~impeded global supply chains,~~ resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash ~~flows throughout 2021~~flows. Although we are optimistic that the worst of the global macroeconomic volatility is in the past, the direct and indirect impacts on our markets, operations, and financial performance have been unpredictable. As a result of this continued uncertainty, there may still be impacts on our industry, operations, workforce, supply chains, distribution systems, and demand for our products in the future which cannot be reasonably estimated at this time.

Additionally, the United States and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. As a result of the conflict, the United States, United Kingdom, European Union and other countries have levied economic sanctions and bans on Russia and Russia has responded with its own retaliatory measures. These measures have impacted the price of certain raw materials and energy and could have a lasting impact on regional and global economies.

Our facility in Vynohradiv is on the far western corner within the Transcarpathia region of Ukraine near the Hungary border. In 2022, products manufactured at our Ukraine facility represented approximately 8% of the Company’s total revenue, including automotive cables, seat heaters and steering wheel heaters. At this time, our Ukraine facility is operating at normal levels and we continue to execute contingency plans and, in coordination with certain customers, specific equipment and production relocations leveraging our flexible global manufacturing footprint. Certain of our employees in Ukraine are routinely conscripted into ~~2022.~~the military and/or sent to the Russian border to fight in the ongoing conflict. We ~~expect these inflationary impacts~~have incurred, and will likely continue to incur costs to support our employees and relocate equipment and production based on customer and company needs. Further, most of our products manufactured in Ukraine are shipped across the border from Ukraine to Hungary for further delivery to our customers. If that border crossing were to be closed or restricted for any reason, we may experience a significant disruption to our operations. Our response to the ongoing conflict is based on a severity level contingency response plan that has been developed with certain customers. As the situation in Ukraine is very fluid, we continue ~~for the foreseeable future.~~to monitor its effects on our business and we continue to work closely with our customers to adjust our contingency response as necessary.

Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events. The Company was able to mitigate the impacts of supply chain disruptions in order to satisfy customer orders during the first three quarters of 2021; however, during the fourth quarter of 2021 and continuing into 2022 we havehas experienced and may continue to experience direct ~~adverse~~ impacts of ongoing shortages of semiconductors. Our ability to meet customer orders without significant delay and/or expense ~~for the remainder of 2022 and beyond~~ remains subject to significant uncertainty.

Global inflation has increased significantly beginning in 2021. Changing costs of freight, materials, equipment, labor and other inputs used to manufacture and sell our products and logistics costs, in particular, have impacted and may in the future impact operating costs and, accordingly, may affect the prices of our products. We are involved in continuing programs to mitigate the impact

of cost increases through identification of sourcing and manufacturing efficiencies where possible. However, there have been, and there may still be, impacts we are not able to fully mitigate or pass through the increases in our operating costs.

We are exposed to foreign currency risk due to the translation and remeasurement of the results of certain international operations into U.S. Dollars as part of the consolidation process. Therefore, fluctuations in foreign currency exchange rates can create volatility in the results of operations and may adversely affect our financial condition.

In response to the global supply chain instability and inflationary cost increases, the Company has taken several actions to minimize any potential and actual adverse impacts by working closely with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. We expect global supply chain instability will continue to have an adverse impact on our business and financial performance for the foreseeable future, and such adverse impact may be material. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy continue to evolve. Accordingly, the significance of the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.

In addition to the direct and indirect impacts of COVID-19, the United States and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. As a result of the conflict, the United States, United Kingdom, European Union and other countries have levied economic sanctions and bans on Russia and Russia has responded with its own retaliatory measures. These measures have impacted the availability and price of certain raw materials and could have a lasting impact on regional and global economies.

Our facility in Vynohradiv is on the far western corner of Ukraine near the Hungary border. In 2021, products manufactured at our Ukraine facility represented approximately 11% of the Company’s total revenue, including automotive cables, seat heaters and steering wheel heaters. At this time, our Ukraine facility is operating at normal levels and we have begun executing contingency plans and, in coordination with certain customers, specific equipment and production relocations leveraging our flexible global manufacturing footprint. Our response to the escalating situation is based on a severity level contingency response plan that has been developed with certain customers. As the situation in Ukraine is very fluid, we continue to monitor its effects on our business and we continue to work closely with our customers to adjust our contingency response as necessary.

Acquisitions

On May 4, 2022, the Company entered into a definitive purchase agreement to acquire the automotive business of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. Also on May 4, 2022, the Company entered into a put and call option agreement with one of the owners of Alfmeier for the real property in Germany on which Alfmeier’s headquarters is located. Pursuant to this agreement, the seller had a put to sell the headquarters to the Company and the Company had an option to purchase the headquarters post-closing of the acquisition of Alfmeier. Prior to the closing of the acquisition, Alfmeier and certain of its subsidiaries completed a series of carve-out transactions such that Alfmeier’s industrial and non-automotive business would not be acquired by the Company. On July 29, 2022, the Company completed the acquisition of Alfmeier through the acquisition of all shares in Alfmeier for a total purchase price of €181.5 million (approximately $184.9 million at foreign exchange rates as of such date), net of cash and cash-like items on one hand, and debt and debt-like items on the other hand, and subject to customary adjustments related to Alfmeier’s net working capital as of the closing. The Alfmeier purchase price was increased by €4.0 million (approximately $4.1 million at foreign exchange rates as of such date) at closing as a result of the resolution of certain Alfmeier tax matters prior to closing. Also, on July 29, 2022, the Company completed the acquisition of Alfmeier’s headquarters for a purchase price of €10.5 million (approximately $10.7 million at foreign exchange rates as of such date). The transactions were funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. ~~(“IOB”).~~ Dacheng, a privately held ~~company headquartered in Jiangmen, Guangdong Province, China, is a~~ manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition ~~provides~~provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, ~~while also expanding~~and expanded overall manufacturing capacity to include a low-cost manufacturing site. The ~~Company acquired all shares in Dacheng for $34.3 million, net of cash and debt, and subject to customary adjustments related to Dacheng’s net working capital as of the closing.~~total consideration transferred was $35.0 million. The purchase ~~price may be increased by up to $3.0 million post-closing~~agreement also included potential cash payments contingent upon the achievement of certain ~~milestones. Also, as part~~performance metrics and continued employment of the transaction but not the purchase price or net working capital, IOB retained the obligation to satisfy an existing $2.7 million consulting fee for work performed on IOB’s behalf. The transaction was fundedformer majority shareholder through a ~~combination~~series of defined dates. The achievement of these performance metrics resulted in cash payments of $0.5 million. These cash payments were accounted for as compensation expense and recorded as a component of selling, general and administrative expense ratably over the service period.

On August 1, 2022, the Company acquired 100% of the ~~Company’s existing cash balances~~equity interests of Alfmeier Präzision SE (“Alfmeier”) a global leader in automotive lumbar and ~~borrowings under~~massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the ~~Revolving Credit Facility.~~Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned well with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration for this acquisition was $170.7 million.

25See Note 2, “Acquisitions” to the consolidated condensed financial statements included in this Report for additional information.

Impairments – Non-Automotive Electronics Business

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $9.4 million, $5.6 million and $0.7 million for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.

During the three months ended March 31, 2023, the Company recorded non-cash impairment charges of $1.4 million for the write down of inventory within the Automotive segment. This charge is recorded in Cost of sales.

The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.

Light Vehicle Production Volumes

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. According to the forecasting firm ~~IHS Markit (July 2022~~S&P Global Mobility (April 2023 release), ~~actual~~

global light vehicle production in the three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 in the Company’s key markets of North America, Europe, China, Japan and Korea, as compared to the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, are shown below (in millions of units):


	Three Months Ended June 30,							Six Months Ended June 30,							Three Months Ended March 31,
	2022		2021		% Change			2022		2021		% Change			2023		2022		% Change
North America		3.6		3.2		12.5	%		7.1		6.8		4.4	%		3.9		3.6		9.8	%
Europe		3.9		4.1		(4.9	)%		7.9		8.9		(11.2	)%		4.6		3.9		17.2	%
Greater China		5.5		5.8		(5.2	)%		11.7		11.6		0.9	%		5.7		6.2		(7.8	)%
Japan / South Korea		2.5		2.8		(10.7	)%		5.2		5.8		(10.3	)%		3.1		2.7		16.9	%
Total light vehicle production volume in key markets		15.5		15.9		(2.6	)%		31.9		33.1		(3.7	)%		17.4		16.4		6.0	%

The ~~IHS Markit (July 2022~~S&P Global Mobility (April 2023 release) forecasted light vehicle production volume in the Company’s key markets for full year ~~2022~~2023 to increase to ~~67.2~~70.4 million units, a ~~3.9%~~4.1% increase from full year ~~2021~~2022 light vehicle production volumes. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, these forecasts generally are updated monthly, and future forecasts may be significantly different from period to period due to changes in macroeconomic conditions or matters specific to the automotive ~~industry, such as the fluctuations that occurred in 2020 and remain ongoing due to the direct and indirect impacts of the COVID-19 pandemic.~~industry. Further, due to differences in regional product mix at our manufacturing facilities, as well as material production schedules from our customers for our products on specific vehicle programs, our future forecasted results do not directly correlate with the global and/or regional light vehicle production forecasts of ~~IHS Markit~~S&P Global Mobility or other third-party sources.

New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the ~~second~~first quarter of ~~2022,~~2023, we secured new automotive business awards totaling ~~$600.0~~$480 million in the ~~quarter including $190.0 million secured by Alfmeier Präzision SE prior to acquisition closing.~~quarter. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by our customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of ~~June 30, 2022,~~March 31, 2023, the date of this Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in the ~~second~~first quarter ~~2022~~2023 also do not reflect, in particular, the impact of ~~the COVID-19 pandemic~~macroeconomic and ~~related macroeconomic~~geopolitical challenges on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties that are included in this Report or incorporated by reference in “Forward-Looking Statements” above.

Stock Repurchase Program

OnIn December ~~11,~~ 2020, the Board of Directors authorized a ~~new~~ stock repurchase program (the “2020 Stock Repurchase Program”) ~~to commence upon expiration of the prior stock repurchase program on December 15, 2020.~~. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding Common Stock over a three-year period, expiring December 15, 2023. Repurchases under the 2020 Stock Repurchase Program may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the ~~six~~three months ended ~~June 30, 2022, we did not make any repurchases~~March 31, 2023, the Company repurchased $10.0 million of shares under the 2020 Stock Repurchase Program ~~and have a remaining~~with an average price paid per share of $59.27. The 2020 Stock Repurchase Program had $120.0 million repurchase authorization ~~of $130.0 million~~remaining as of ~~June 30, 2022.~~March 31, 2023.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.

See Note 14, “Segment Reporting”, to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating ~~income.~~income (loss). The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

Consolidated Results of Operations

The results of operations for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ in thousands, were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,									Three Months Ended March 31,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)			2023			2022			Favorable / (Unfavorable)
Product revenues	$	260,715		$	266,005		$	(5,290	)	$	528,372		$	554,540		$	(26,168	)	$	363,625		$	267,657		$	95,968
Cost of sales		201,338			186,792			(14,546	)		404,882			387,658			(17,224	)		282,495			203,544			(78,951	)
Gross margin		59,377			79,213			(19,836	)		123,490			166,882			(43,392	)		81,130			64,113			17,017
Operating expenses:
Net research and development expenses		19,325			18,227			(1,098	)		39,759			35,830			(3,929	)		25,145			20,434			(4,711	)
Selling, general and administrative expenses		31,943			27,223			(4,720	)		61,251			55,749			(5,502	)		37,042			29,308			(7,734	)
Restructuring expenses		374			2,091			1,717			555			2,882			2,327			1,269			181			(1,088	)
Total operating expenses		51,642			47,541			(4,101	)		101,565			94,461			(7,104	)		63,456			49,923			(13,533	)
Operating income		7,735			31,672			(23,937	)		21,925			72,421			(50,496	)		17,674			14,190			3,484
Interest expense, net		(1,430	)		(630	)		(800	)		(1,999	)		(1,669	)		(330	)		(4,144	)		(569	)		(3,575	)
Foreign currency gain (loss)		4,552			(515	)		5,067			6,769			258			6,511
Foreign currency (loss) gain																				(2,069	)		2,217			(4,286	)
Other income		134			12			122			338			3			335			230			204			26
Earnings before income tax		10,991			30,539			(19,548	)		27,033			71,013			(43,980	)		11,691			16,042			(4,351	)
Income tax expense		3,919			5,748			1,829			8,214			13,313			5,099			3,728			4,295			567
Net income	$	7,072		$	24,791		$	(17,719	)	$	18,819		$	57,700		$	(38,881	)	$	7,963		$	11,747		$	(3,784	)

Product revenues by product category, in thousands, for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ were as follows:

Three Months Ended June 30,

Six Months Ended June 30,

2022

2021

% Change

$ Change

2022

2021

% Change

$ Change

Climate Control Seat

$
96,488

$
98,229

(1.8
)%

$
(1,741
)

$
199,222

$
207,402

(3.9
)%

$
(8,180
)
Seat Heaters

65,903

69,864

(5.7
)%

$
(3,961
)

134,799

146,585

(8.0
)%

$
(11,786
)
Steering Wheel Heaters

28,951

26,697

8.4
%

$
2,254

57,687

55,561

3.8
%

$
2,126

Automotive Cables

19,280

22,940

(16.0
)%

$
(3,660
)

41,325

47,221

(12.5
)%

$
(5,896
)
Battery Performance Solutions

17,451

17,577

(0.7
)%

$
(126
)

35,064

35,337

(0.8
)%

$
(273
)
Electronics

10,278

14,652

(29.9
)%

$
(4,374
)

21,106

29,757

(29.1
)%

$
(8,651
)
Other Automotive

10,801

5,146

109.9
%

$
5,655

17,813

12,612

41.2
%

$
5,201

Subtotal Automotive segment

249,152

255,105

(2.3
)%

$
(5,953
)

507,016

534,475

(5.1
)%

$
(27,459
)
Medical segment

11,563

10,900

6.1
%

$
663

21,356

20,065

6.4
%

$
1,291

Total Company

$
260,715

$
266,005

(2.0
)%

$
(5,290
)

$
528,372

$
554,540

(4.7
)%

$
(26,168
)


	Three Months Ended March 31,
	2023		2022		$ Change			% Change
Climate Control Seat	$	114,753	$	102,734	$	12,019			11.7	%
Seat Heaters		75,636		68,896		6,740			9.8	%
Lumbar and Massage Comfort Solutions		38,738		—		38,738			100.0	%
Steering Wheel Heaters		36,347		28,736		7,611			26.5	%
Valve Systems		26,994		—		26,994			100.0	%
Battery Performance Solutions		20,309		17,613		2,696			15.3	%
Automotive Cables		20,220		22,045		(1,825	)		(8.3	)%
Electronics		10,970		10,828		142			1.3	%
Other Automotive		8,725		7,012		1,713			24.4	%
Subtotal Automotive segment		352,692		257,864		94,828			36.8	%
Medical segment		10,933		9,793		1,140			11.6	%
Total Company	$	363,625	$	267,657	$	95,968			35.9	%

Product Revenues

Below is a summary of our product revenues, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

Variance Due To:

2022

2021

Favorable /
(Unfavorable)

Automotive Volume

FX

Pricing/Other

Total

Product revenues

$
260,715

$
266,005

$
(5,290
)

$
4,388

$
(13,569
)

$
3,891

$
(5,290
)


	Three Months Ended March 31,						Variance Due To:
	2023		2022		Favorable / (Unfavorable)		Automotive Volume		FX			Acquisitions		Pricing/Other		Total
Product revenues	$	363,625	$	267,657	$	95,968	$	36,804	$	(8,131	)	$	67,011	$	284	$	95,968

Product revenues for the three months ended ~~June 30, 2022 decreased 2.0%~~March 31, 2023 increased 35.9% as compared to the three months ended ~~June 30, 2021.~~March 31, 2022. The ~~decrease~~increase in product revenues is ~~related~~due to favorable volumes in our Automotive segment, the inclusion of sales from Alfmeier and Dacheng since the acquisitions, and the negotiation of lower annual price reductions and cost recoveries from customers, partially offset by unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi, ~~and~~ Korean Won, partially offset by increased volumes in our Automotive segment. The increase in product revenues included in Variance Due To Pricing/Other is primarily attributable to price increases as a result of initial cost recoveries from customers in our Automotive segment and negotiated lower annual price reductions from customers. Additional increase in product revenues included in Variance Due To Pricing/Other is a result of an increase in product revenue in our Medical segment.

~~Below is a summary of our product revenues, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

Variance Due To:

2022

2021

Favorable /
(Unfavorable)

Automotive Volume

FX

Pricing/Other

Total

Product revenues

$
528,372

$
554,540

$
(26,168
)

$
(8,582
)

$
(20,170
)

$
2,584

$
(26,168
)

Product revenues for the six months ended June 30, 2022 decreased 4.7% as compared to the six months ended June 30, 2021. The decrease in product revenues is primarily related to decreased volumes in our Automotive segment and unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi and Korean Won. The increase in product revenues included in Variance Due To Pricing/Other is primarily attributable to price increases as a result of initial cost recoveries from customers in our Automotive segment and negotiated lower annual price reductions from customers. Additional increase in product revenues included in Variance Due To Pricing/Other is a result of an increase in product revenue in our Medical segment.Japanese Yen.

Cost of Sales

Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:


	Three Months Ended June 30,									Variance Due To:															Three Months Ended March 31,									Variance Due To:
	2022			2021			Favorable / (Unfavorable)			Automotive Volume			Operational Performance			FX			Other			Total			2023			2022			Favorable / (Unfavorable)			Automotive Volume			Operational Performance		FX			Acquisitions and Other			Total
Cost of sales	$	201,338		$	186,792		$	(14,546	)	$	(2,727	)	$	(13,472	)	$	7,280		$	(5,627	)	$	(14,546	)	$	282,495		$	203,544		$	(78,951	)	$	(22,055	)	$	3,745	$	4,327		$	(64,968	)	$	(78,951	)
Gross margin	$	59,377		$	79,213		$	(19,836	)	$	1,661		$	(13,472	)	$	(6,289	)	$	(1,736	)	$	(19,836	)	$	81,130		$	64,113		$	17,017		$	14,749		$	1,634	$	(3,803	)	$	4,437		$	17,017
Gross margin - Percentage of product revenues		22.8	%		29.8	%																				22.3	%		24.0	%

Cost of sales for the three months ended ~~June 30, 2022~~March 31, 2023 increased ~~7.8%~~38.8% as compared to the three months ended ~~June 30, 2021.~~March 31, 2022. The increase in cost of sales is primarily due to increased volumes in our Automotive segment, ~~and~~the inclusion of expenses from the acquired businesses, inflation associated with ~~higher freight costs~~wages and material costs, ~~included in the Variance Due To Operational Performance. This increase was~~and a non-automotive electronics inventory charge. These increases were partially offset by favorable foreign currency impacts primarily attributable to the Euro, Chinese Renminbi and ~~Chinese Renminbi. The increase in cost of sales included in Variance Due To Other above is due to the following items:~~Ukrainian Hryvnia and lower expedited freight costs.

•

~~$3.2 million of increase due to wage inflation; and~~

•

~~$1.3 million of increase attributable to higher volumes in the Medical segment~~

~~Below is a summary of our cost of sales and gross margin, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

Variance Due To:

2022

2021

Favorable /
(Unfavorable)

Automotive Volume

Operational
Performance

FX

Other

Total

Cost of sales

$
404,882

$
387,658

$
(17,224
)

$
5,621

$
(25,480
)

$
11,197

$
(8,562
)

$
(17,224
)
Gross margin

$
123,490

$
166,882

$
(43,392
)

$
(2,961
)

$
(25,480
)

$
(8,973
)

$
(5,978
)

$
(43,392
)
Gross margin - Percentage of product revenues

23.4
%

30.1
%

Cost of sales for the six months ended June 30, 2022 increased 4.4% as compared to the six months ended June 30, 2021. The increase in cost of sales within the Variance Due To Operational Performance is primarily related to inflation associated with higher freight costs and material costs. This increase was partially offset by decreased volumes in our Automotive segment and favorable foreign currency impacts primarily attributable to the Euro and Chinese Renminbi. The increase in cost of sales included in Variance Due To Other above is due to the following items:

•

~~$6.5 million of increase due to wage inflation;~~

•

~~$2.0 million of increase attributable to higher volumes in the Medical segment; and~~

•

~~$0.7 million of decrease due to lower stock compensation expense.~~

Net Research and Development Expenses

Below is a summary of our net research and development expenses, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:


	Three Months Ended June 30,									Three Months Ended March 31,
	2022			2021			Favorable / (Unfavorable)			2023			2022			Favorable / (Unfavorable)
Research and development expenses	$	24,334		$	23,013		$	(1,321	)	$	31,749		$	23,903		$	(7,846	)
Reimbursed research and development expenses		(5,009	)		(4,786	)		223			(6,604	)		(3,469	)		3,135
Net research and development expenses	$	19,325		$	18,227		$	(1,098	)	$	25,145		$	20,434		$	(4,711	)
Percentage of product revenues		7.4	%		6.9	%					6.9	%		7.6	%

Net research and development expenses for the three months ended ~~June 30, 2022~~March 31, 2023 increased ~~6.0%~~23.1% as compared to the three months ended ~~June 30, 2021.~~March 31, 2022. The increase in net research and development expenses is primarily related to the inclusion of net expenses from Alfmeier and increased ~~project-related spending.~~

~~Below is a summary of our net research and development expenses, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Research and development expenses

$
48,237

$
45,439

$
(2,798
)
Reimbursed research and development expenses

(8,478
)

(9,609
)

(1,131
)
Net research and development expenses

$
39,759

$
35,830

$
(3,929
)
Percentage of product revenues

7.5
%

6.5
%

~~Net research and development expenses for the six months ended June 30, 2022 increased 11.0% as compared~~investments to the six months ended June 30, 2021. The increase in net research and development expenses is primarily related to increased project-related spending and lower reimbursements for costs to design, develop and purchase tooling pursuant to customer contracts.support new program wins.

Selling, General and Administrative Expenses

Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:


	Three Months Ended June 30,									Three Months Ended March 31,
	2022			2021			Favorable / (Unfavorable)			2023			2022			Favorable / (Unfavorable)
Selling, general and administrative expenses	$	31,943		$	27,223		$	(4,720	)	$	37,042		$	29,308		$	(7,734	)
Percentage of product revenues		12.3	%		10.2	%					10.2	%		10.9	%

Selling, general and administrative expenses for the three months ended ~~June 30, 2022~~March 31, 2023 increased ~~17.3%~~26.4% as compared to the three months ended ~~June 30, 2021.~~March 31, 2022. The increase in selling, general and administrative expenses is primarily related to ~~acquisition related costs.~~

~~Below is a summary~~the inclusion of ~~our selling, general~~expenses from acquired businesses and ~~administrative expenses, in thousands, for the six months ended June 30, 2022 and 2021:~~higher compensation expenses.

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Selling, general and administrative expenses

$
61,251

$
55,749

$
(5,502
)
Percentage of product revenues

11.6
%

10.1
%

Selling, general and administrative expenses for the six months ended June 30, 2022 increased 9.9% as compared to the six months ended June 30, 2021. The increase in selling, general and administrative expenses is primarily related to acquisition related costs.

Restructuring Expenses

Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead expenses.

Below is a summary of our restructuring expenses, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Restructuring expenses

$
374

$
2,091

$
1,717


	Three Months Ended March 31,
	2023		2022		Favorable / (Unfavorable)
Restructuring expenses	$	1,269	$	181	$	(1,088	)

During the three months ended ~~June 30, 2022,~~March 31, 2023, the Company recognized expenses of $0$1.2 million for employee separation costs and ~~$0.4~~less than $0.1 million for other costs. These restructuring expenses primarily relate to discrete restructuring actions focused on the reduction of global overhead expenses.

During the three months ended ~~June 30, 2021, the Company recognized expenses of $1.5 million for employee separation costs and $0.6 million of accelerated depreciation and other costs.~~

~~Below is a summary of our restructuring expenses, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Restructuring expenses

$
555

$
2,882

$
2,327

~~During the six months ended June 30,~~March 31, 2022, the Company recognized expenses of $0.1 million for employee separation costs and ~~$0.5~~$0.1 million for ~~other costs.~~

~~During the six months ended June 30, 2021, the Company recognized expenses of $2.0 million for employee separation costs and $0.9 million of accelerated depreciation and~~ other costs.

See Note 3, “Restructuring” ofto the consolidated condensed financial statements included in this Report for additional information.

Interest Expense, net

Below is a summary of our interest expense, net, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Interest expense, net

$
(1,430
)

$
(630
)

$
(800
)


	Three Months Ended March 31,
	2023			2022			Favorable / (Unfavorable)
Interest expense, net	$	(4,144	)	$	(569	)	$	(3,575	)

Interest expense, net for the three months ended ~~June 30, 2022~~March 31, 2023 increased ~~127.0%~~628.3% as compared to the three months ended ~~June 30, 2021.~~March 31, 2022. The increase is primarily ~~due~~related to ~~the change in fair value of the interest rate swap derivative during the three months ended June 30, 2022.~~

~~Below is~~ a ~~summary of our interest expense, net, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Interest expense, net

$
(1,999
)

$
(1,669
)

$
(330
)

Interest expense, net for the six months ended June 30, 2022 increased 19.8% as compared to the six months ended June 30, 2021. The increase is primarily due to the change in fair value of the interest rate swap derivative during the six months ended June 30, 2022 offset by a lowerhigher balance on our revolving credit agreement during the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, as compared to the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022 and the mark to market impact of the Company’s interest rate swap during the three months ended March 31, 2023. See Note 6, "Debt," to the consolidated condensed financial statements included in this Report for additional information.

Foreign Currency (Loss) Gain ~~(Loss)~~

Below is a summary of our foreign currency (loss) gain, ~~(loss),~~ in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Foreign currency gain (loss)

$
4,552

$
(515
)

$
5,067


	Three Months Ended March 31,
	2023			2022		Favorable / (Unfavorable)
Foreign currency (loss) gain	$	(2,069	)	$	2,217	$	(4,286	)

Foreign currency (loss) gain for the three months ended ~~June 30, 2022~~March 31, 2023 included net realized foreign currency gain of ~~$0.5~~$3.8 million and net unrealized foreign currency loss of $5.9 million.

Foreign currency (loss) gain for the three months ended March 31, 2022 primarily included net realized foreign currency loss of $0.1 million and net unrealized foreign currency gain of ~~$4.0 million.~~

~~Foreign currency loss for the three months ended June 30, 2021 primarily included net realized foreign currency loss of $0.5 million.~~

~~Below is a summary of our foreign currency gain, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Foreign currency gain

$
6,769

$
258

$
6,511

~~Foreign currency gain for the six months ended June 30, 2022 included net realized foreign currency gain of $0.4 million and net unrealized foreign currency gain of $6.4 million.~~

~~Foreign currency gain for the six months ended June 30, 2021 primarily included net unrealized foreign currency gain of $0.3~~$2.3 million.

Other Income

Below is a summary of our other income, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Other income

$
134

$
12

$
122


	Three Months Ended March 31,
	2023		2022		Favorable / (Unfavorable)
Other income	$	230	$	204	$	26

~~The increase in~~ Other income ~~is due to an increase in miscellaneous income.~~

~~Below is a summary of our other income, in thousands,~~ for the ~~six~~three months ended ~~June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Other income

$
338

$
3

$
335

~~The increase in Other income is due~~March 31, 2023 remained flat as compared to ~~an increase in miscellaneous income.~~the three months ended March 31, 2022.

Income Tax Expense

Below is a summary of our income tax expense, in thousands, for the three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Income tax expense

$
3,919

$
5,748

$
1,829


	Three Months Ended March 31,
	2023		2022		Favorable / (Unfavorable)
Income tax expense	$	3,728	$	4,295	$	567

Income tax expense was ~~$3.9~~$3.7 million for the three months ended ~~June 30, 2022,~~March 31, 2023, on earnings before income tax of ~~$11.0~~$11.7 million, representing an effective tax rate of ~~35.7%~~31.9 %. The tax amount included the effect of the settlement and closure of a multi-year state audit of $0.5 million. Adjusted for the audit impacts, the effective rate was 28.0%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”), and the ~~increase of accruals~~quarterly accrual for uncertain tax positions, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects on ~~equity~~stock compensation vesting.

Income tax expense was ~~$5.7~~$4.3 million for the three months ended ~~June 30, 2021~~March 31, 2022 on earnings before income tax of ~~$30.5~~$16.0 million representing an effective tax rate of ~~18.8%~~26.8%. The effective tax rate differed from the U.S. Federal statutory rate of ~~21% primarily due to certain favorable tax effect on equity vesting and intercompany transactions in the second quarter of 2021, partially offset by unfavorable impact of GILTI.~~

~~Below is a summary of our income tax expense, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Income tax expense

$
8,214

$
13,313

$
5,099

Income tax expense was $8.2 million for the six months ended June 30, 2022, on earnings before income tax of $27.0 million, representing an effective tax rate of 30.4%. The effective tax rate differed from the U.S. Federal statutory rate of 21%21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the

GILTI, and the ~~increase of accruals~~quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects ~~of equity~~on stock compensation vesting.

Income tax expense was $13.3 million for the six months ended June 30, 2021 on earnings before income tax of $71.0 million representing an effective tax rate of 18.7%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to certain favorable tax effect on equity vesting and intercompany transactions in 2021, partially offset by the unfavorable impact of GILTI.

Liquidity and Capital Resources

Overview

Our primary sources of liquidity and capital resources are cash flows from operations and borrowings available under our Second Amended and Restated Credit Agreement. Our cash requirements consist principally of working capital, capital expenditures, research and development, operating lease payments, income tax payments and general corporate purposes. We generally reinvest available cash flows from operations into our business, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition and investment opportunities that will enhance our business strategies.

As of ~~June 30, 2022,~~March 31, 2023, the Company had ~~$157.3~~$166.6 million of cash and cash equivalents, ~~$357.0~~$266.4 million of availability under our Second Amended and Restated Credit Agreement and $32.4 million of availability under our North America receivables factoring arrangement. Significant changes in liquidity occurred during July 2022 in connection with the close of the Alfmeier and Dacheng acquisitions. See "Material Cash Requirements" below for further information.Agreement. We ~~continue to maintain access to the capital markets and~~ may issue debt or equity securities, which may provide an additional source of liquidity. ~~There~~However, there can be no assurance equity or debt financing will be available to us when we need it or, if available, the terms will be satisfactory to us and not dilutive to our then-current shareholders.

We continue to expect to be able to move funds between different countries to manage our global liquidity needs without material adverse tax implications, subject to current monetary policies and the terms of the Second Amended and Restated Credit Agreement. We utilize a combination of strategies, including dividends, cash pooling arrangements, intercompany loan repayments and other distributions and advances to provide the funds necessary to meet our global liquidity needs. There are no significant restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Gentherm Incorporated. As of ~~June 30, 2022,~~March 31, 2023, the Company’s cash and cash equivalents held by our non-U.S. subsidiaries totaled approximately ~~$141.1~~$134.0 million. If additional non-U.S. cash was needed for our U.S. operations, we may be required to accrue and pay withholding if we were to distribute such funds from non-U.S. subsidiaries to the U.S.; however, based on our current liquidity needs and strategies, we do not anticipate a need to accrue and pay such additional amounts.

We currently believe that our cash and cash equivalents, ~~and~~ borrowings available under our Second Amended and Restated Credit Agreement and ~~the North America~~ receivables factoring ~~arrangement~~arrangements, and cash flows from operations will be adequate to meet anticipated cash requirements for at least the next twelve months and the foreseeable future.

Cash and Cash Flows

The following table represents our cash and cash equivalents, in thousands:


	Six Months Ended June 30,						Three Months Ended March 31,
	2022			2021			2023			2022
Cash and cash equivalents at beginning of period	$	190,606		$	268,345		$	153,891		$	190,606
Net Cash (used in) provided by operating activities		(3,686	)		84,362
Net Cash used in investing activities		(15,717	)		(25,859	)
Net Cash used in financing activities		(5,145	)		(139,625	)
Net cash provided by (used in) operating activities								25,109			(684	)
Net cash used in investing activities								(2,549	)		(5,957	)
Net cash used in financing activities								(12,965	)		(3,750	)
Foreign currency effect on cash and cash equivalents		(8,800	)		(360	)		3,144			(2,298	)
Cash and cash equivalents at end of period	$	157,258		$	186,863		$	166,630		$	177,917

Cash Flows From Operating Activities

~~Cash used in~~Net cash provided by (used in) operating activities totaled ~~$3.7~~$25.1 million during the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 primarily reflecting net income of ~~$18.8~~$8.0 million, ~~decreased by non-cash adjustments of $1.0~~$15.6 million for ~~deferred income taxes~~non-cash charges for depreciation, amortization, stock based compensation and ~~$46.6~~loss on disposition of property, $1.7 million related to changes in assets and liabilities and non-cash charges of $1.7 million for inventory provisions, partially offset by ~~$25.1~~non-cash charges of $1.8 million for ~~non-cash charges for depreciation, amortization, non-cash stock based compensation, loss on disposition of property and equipment and pension plan adjustments.~~deferred income taxes.

Cash Flows From Investing Activities

~~Cash~~Net cash used in investing activities was ~~$15.7~~$2.5 million during the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, reflecting purchases of property and equipment of ~~$15.4 million and payments related to an equity method investment for $0.4~~$6.3 million, partially offset by proceeds from ~~the sale~~deferred purchase price of ~~property and equipment~~factored receivables of ~~$0.1~~$3.7 million.

Cash Flows From Financing Activities

~~Cash~~Net cash used in financing activities was ~~$5.1~~$13.0 million during the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, reflecting $10.0 million paid to repurchase common stock, $2.7 million paid for employee taxes ~~withheld~~related to the net settlement of restricted stock units that vested during the year and ~~paid on employees' share based payment awards totaling $4.5~~$0.6 million ~~and repayments~~ of debt ~~of $1.2 million,~~repayments, partially offset by the proceeds from the exercise of Common Stock options totaling ~~$0.6~~$0.3 million.

Debt

The following table summarizes the Company’s debt, in thousands, as of ~~June 30, 2022~~March 31, 2023 and ~~2021:~~December 31, 2022:

June 30, 2022

June 30, 2021

Interest
Rate

Principal
Balance

Interest
Rate

Principal
Balance

Credit Agreement:

U.S. Revolving Note (U.S. Dollar denominations)

2.42
%

$
35,000

1.35
%

$
35,000

U.S. Revolving Note (Euro denominations)

—

—

1.25
%

8,294

DEG Vietnam Loan

5.21
%

2,500

5.21
%

5,000

Total debt

37,500

48,294

Current maturities

(2,500
)

(2,500
)
Long-term debt, less current maturities

$
35,000

$
45,794


	March 31, 2023						December 31, 2022
	Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
Revolving Credit Facility (U.S. Dollar denominations)		6.28	%	$	232,000			5.80	%	$	232,000
Other loans	3.90% - 5.21%				1,555		3.89% - 5.21%				2,011
Finance leases	N/A				999		N/A				1,085
Total debt					234,554						235,096
Current maturities					(1,996	)					(2,443	)
Long-term debt, less current maturities				$	232,558					$	232,653

Credit Agreement

Gentherm, together with certain of its subsidiaries, maintain a revolving credit note ~~(“U.S. Revolving Note”~~(the “Revolving Credit Facility”) under its Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Second Amended and Restated Credit Agreement was entered into on June 10, 2022 and ~~amends~~amended and ~~restates~~restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement has a maximum borrowing capacity of $500 million and matures on June 10, 2027. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. As of March 31, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement.

~~DEG Vietnam Loan~~Finance Leases

~~The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary~~As of ~~KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG~~March 31, 2023 and December 31, 2022, there was ~~used to~~$1.0 million and $1.1 million, respectively, of outstanding finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023.leases.

Other Sources of Liquidity

The Company is party to a receivable factoring ~~agreement~~agreements with ~~HSBC Bank USA, National Association. Under the receivable factoring agreement,~~unrelated third parties under which we can sell receivables for certain ~~of our North America~~ account debtors, ~~up to $41.3 million,~~ on a revolving basis, subject to outstanding balances and concentration limits. The receivable factoring agreements are transferred in their entirety to the acquiring entities and are accounted for as a sale. Some of the agreements, including those assumed through the acquisition of Alfmeier, have deferred purchase price arrangements. As of ~~June 30, 2022,~~March 31, 2023, there were no$3.3 million outstanding receivables transferred under the receivable factoring ~~agreement and our availability under the receivables factoring agreement was $32.4 million.~~agreement.

Material Cash Requirements

Significant liquidity was required during July 2022 to close the Alfmeier and Dacheng acquisitions. In connection with these acquisitions, we drew $202.0 million from the U.S. Revolving Note and made cash payments totaling approximately $232.6 million, including amounts placed in escrow. Additional cash payments may be required for customary adjustments related to Alfmeier’s net working capital as of the closing and for the contingent payments of up to $3.0 million related to the Dacheng acquisition. See "Acquisitions" above for additional information about the purchase prices associated with these transactions.

The Company continues to enter into agreements with suppliers to reserve the right to purchase certain semiconductor chips over periods of 12-24 months. As of ~~June 30, 2022,~~March 31, 2023, the Company’s total commitments for these semiconductor chip agreements was ~~$40.4~~

$40.6 million. See Note 7, “Commitments and Contingencies” ofto the consolidated condensed financial statements included in this Report for additional information.

Except as described above, there have been no material changes in our cash requirements since December 31, ~~2021,~~2022, the end of fiscal year ~~2021.~~2022. See Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 for additional information regarding our material cash requirements.

Effects of Inflation

The automotive component supply industry has historically been subject to inflationary pressures with respect to materials and labor. InBeginning in 2021 and continuing ~~in 2022, macroeconomic effects~~into the first quarter of 2023, the ~~COVID-19 pandemic have resulted in~~industry has experienced inflationary cost increases in certain materials and components, labor and transportation. These inflationary cost increases are expected to continue ~~into~~for the foreseeable future as demand remains elevated and supply remains constrained. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and transportation costs, these strategies, together with commercial negotiations with Gentherm's customers and suppliers have not fully offset to date and may not fully offset our future cost increases. Such inflationary cost increase may increase the cash required to fund our operations by a material amount.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting ~~Policies,”~~Policies” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. There have been no significant changes in our critical accounting policies or critical accounting estimates during the three months ended ~~June 30, 2022.~~March 31, 2023. We are not presently aware of any events or circumstances that would require us to update our estimates, assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. ~~For information on the impact of recently issued accounting pronouncements, see Note 2, “New Accounting Pronouncements” in the consolidated condensed financial statements included in this Report.~~

Recent Accounting Pronouncements

~~For information on the impact of recently issued~~There are no new accounting pronouncements ~~see Note 2, “New Accounting Pronouncements” in~~applicable to the ~~consolidated condensed financial statements included in this Report.~~Company as of March 31, 2023.

3632

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to ~~its~~the Company's debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, acquisitions denominated in foreign currencies, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts that can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, and the ineffective portion of interest rate swaps, if any, to interest expense in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in net cash provided by (used in) ~~provided by~~ operating activities in the Company’s consolidated condensed statements of cash flows.

Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of ~~June 30, 2022~~March 31, 2023 is set forth in Note 9, “Financial Instruments” in the consolidated condensed financial statements included in this Report.

Interest Rate Sensitivity

The table below presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt ~~obligations.~~obligations, excluding finance leases. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. ~~The instruments actual cash flows are denominated in the currency indicated in parentheses.~~

Expected Maturity Date

2022

2023

2024

2025

2026

2027

Total

Fair Value

Liabilities

Long-Term Debt:

Variable rate ($USD)

$
—

$
—

$
—

$
—

$
—

$
35,000

$
35,000

$
35,000

Variable interest rate as of June 30, 2022

2.42
%

2.42
%

Fixed rate ($USD)

$
1,250

$
1,250

$
—

$
—

$
—

$
—

$
2,500

$
2,490

Fixed interest rate

5.21
%

5.21
%

5.21
%


	Expected Maturity Date
	2023		2024		2025		2026		2027			2028		Total			Fair Value
Liabilities
Long-Term Debt:
Variable rate	$	—	$	—	$	—	$	—	$	232,000		$	—	$	232,000		$	232,000
Variable interest rate as of March 31, 2023										6.28	%				6.28	%
Fixed rate	$	1,556	$	—	$	—	$	—	$	—		$	—	$	1,556		$	1,574
Fixed interest rate	3.90% - 5.21%													3.90% - 5.21%

Based on the amounts outstanding as of ~~June 30, 2022,~~March 31, 2023, a hypothetical 100 basis point change (increase or decrease) in interest rates would impact annual interest expense by ~~$0.4~~$2.3 million.

~~In connection with the acquisitions of Alfmeier and Dacheng, we drew $202.0 million from the U.S. Revolving Note in July 2022.~~ To hedge the Company's exposure to interest payment fluctuations on a portion of these borrowings, we entered into a floating-to-fixed interest rate swap agreement with a notional amount of $100.0 million.

3733

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

During the three months ended June 30, 2022, the Company entered into forward contracts with a notional amount of $128.3 million to hedge the foreign currency risk associated with the expected closing of Alfmeier.

Expected Maturity or Transaction Date

Anticipated Transactions and Related Derivatives

2022

Total

Fair Value

USD Functional Currency

Forward Exchange Agreements:

(Receive $MXN / Pay $USD)

Total contract amount

$
14,075

$
14,075

$
588

Average contract rate

21.31

21.31

(Receive $EUR / Pay $USD)

Total contract amount

$
128,319

$
128,319

$
482

Average contract rate

0.96

0.96


	Expected Maturity or Transaction Date
Anticipated Transactions and Related Derivatives	2023		2024		2025		Total		Fair Value
USD Functional Currency
Forward Exchange Agreements:
(Receive MXN / Pay USD)
Total contract amount	$	42,078	$	27,030	$	—	$	69,108	$	6,474
Average contract rate		20.32		21.09		—		20.62

The table below presents the potential gain and loss in fair value for the foreign currency derivative contracts from a hypothetical 10% change in quoted currency exchange rates.

June 30, 2022

December 31, 2021

Exchange Rate Sensitivity

Potential loss in fair value

Potential gain in fair value

Potential loss in fair value

Potential gain in fair value

Forward Exchange Agreement:(Receive $MXN / Pay $USD)

$
1,332

$
1,628

$
1,296

$
1,584

Forward Exchange Agreement:(Receive $EUR / Pay $USD)

$
33,300

$
40,700

$
—

$
—


	March 31, 2023				December 31, 2022
Exchange Rate Sensitivity	Potential loss in fair value		Potential gain in fair value		Potential loss in fair value		Potential gain in fair value
Forward Exchange Agreement:(Receive MXN / Pay USD)	$	6,888	$	8,419	$	3,999	$	4,888

The model assumes a parallel shift in currency exchange rates; however, currency exchange rates rarely move in the same direction. The assumption that currency exchange rates change in a parallel fashion may overstate the impact of changing currency exchange rates on assets and liabilities denominated in currencies other than the U.S. dollar.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of ~~June 30, 2022.~~March 31, 2023. As defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), disclosure controls and procedures are controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported on a timely basis, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of ~~June 30, 2022.~~March 31, 2023.

(b) Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the three months ended ~~June 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

3935

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of business, however there is no material pending litigation to which we are a party and no material legal proceeding was terminated, settled or otherwise resolved during the three months ended ~~June 30, 2022.~~March 31, 2023.

ITEM 1A. RISK FACTORS

The Company’s risk factors have not materially changed from those previously disclosed in Part 1, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2021, as amended by Part II “Item 1A. Risk Factors” in our Current Report on Form 10-Q for~~2022. You should carefully consider the ~~three months ended March 31, 2022.~~risks and uncertainties described therein.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities During First Quarter ~~2022~~2023

Period

(a)
Total Number
of Shares
Purchased

(b)
Average Price
Paid Per Share

(c)
Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs

(d)
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)

April 1, 2022 to April 30, 2022

—

$
—

—

$
130,000,105

May 1, 2022 to May 31, 2022

—

$
—

—

$
130,000,105

June 1, 2022 to June 30, 2022

—

$
—

—

$
130,000,105


Period	(a) Total Number of Shares Purchased		(b) Average Price Paid Per Share		(c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs		(d) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)
January 1, 2023 to January 31, 2023		—	$	—		—	$	—
February 1, 2023 to February 28, 2023		—	$	—		—	$	—
March 1, 2023 to March 31, 2023		168,675	$	59.27		168,675	$	120,003,511

(1)

4036

ITEM 6. EXHIBITS

Exhibits to this Report are as follows:

Incorporated by Reference

Exhibit

Number

Exhibit Description

Filed

/Furnished

Herewith

Form

Period

Ending

Exhibit /
Appendix Number

Filing Date

3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18

3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16

31.1

Section 302 Certification – CEO

31.2

Section 302 Certification – CFO

32.1*

Section 906 Certification – CEO

32.2*

Section 906 Certification – CFO

101.INS

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

��

104

Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)

Incorporated by Reference
Exhibit
Number

Exhibit Description

Filed
/Furnished
Herewith

Form

Period
Ending

Exhibit /
Appendix Number

Filing Date
  2.1*

Share Purchase and Transfer Agreement, dated May 4, 2022, by and among Gebhardt Holding GmbH, ELBER GmbH, Gentherm GmbH, and Andreas Gebhardt, Markus Gebhardt and Dr. Johann Vielberth.

10-Q

3/31/22

2.1

5/4/22
  3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18
  3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16
  10.1*

Second Amended and Restated Credit Agreement, dated as of June 10, 2022, by and among Gentherm Incorporated, Gentherm (Texas), Inc., Gentherm Licensing, Limited Partnership, Gentherm Medical, LLC, Gentherm GmbH, Gentherm Enterprises GmbH and Gentherm Licensing GmbH, the lenders party thereto, and Bank of America, N.A., as administrative agent, swing line lender and L/C issuer.

8-K

10.1

6/13/22
  10.2*

Second Amended and Restated Pledge and Security Agreement, dated as of June 10, 2022, by and among Gentherm Incorporated, Gentherm (Texas), Inc., Gentherm Medical, LLC, Gentherm Properties I, LLC, Gentherm Properties II, LLC and Bank of America, N.A.

8-K

10.2

6/13/22
  31.1

Section 302 Certification – CEO

X

  31.2

Section 302 Certification – CFO

X

  32.1**

Section 906 Certification – CEO

X

  32.2**

Section 906 Certification – CFO

X

101.INS

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

X

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

X

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

X

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

X

104

Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)

X

* Schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish any omitted schedules or exhibits upon the request of the SEC. A list of the omitted schedules and exhibits to Exhibit 10.1 is set forth in the agreement. A list of the omitted schedules and exhibits to Exhibit 10.2 is as follows: Schedule I – Pledged Equity Interests; Schedule II – Primary Location, Filing Locations, Trade Names, Changes in Names, State Organizational Numbers, Taxpayer Identification Numbers, Government Contracts, Deposit Accounts, Securities Accounts, Commodity Accounts, Letter of Credit Rights and Commercial Tort Claims; Schedule III – Intellectual Property; Annex I – Security Agreement Supplement.

** Documents are furnished not filed.

4137

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Gentherm Incorporated

	/s/ PHILLIP EYLER
	Phillip Eyler
	President and Chief Executive Officer
	(Principal Executive Officer)

	Date: ~~August 2, 2022~~April 27, 2023


	/s/ MATTEO ANVERSA
	Matteo Anversa
	Executive Vice President, Chief Financial Officer and Treasurer
	(Principal Financial Officer)

	Date: ~~August 2, 2022~~April 27, 2023

4238


	June 30, 2022						June 30, 2021
	Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
U.S. Revolving Note (U.S. Dollar denominations)		2.42	%	$	35,000			1.35	%	$	35,000
U.S. Revolving Note (Euro denominations)		—			—			1.25	%		8,294
DEG Vietnam Loan		5.21	%		2,500			5.21	%		5,000
Total debt					37,500						48,294
Current maturities					(2,500	)					(2,500	)
Long-term debt, less current maturities				$	35,000					$	45,794